Aug 3, 2017

Federal Circuit Affirms Inequitable Conduct Ruling Imposed in Part as Sanction for Litigation Misconduct

On July 27, 2017, a Federal Circuit panel affirmed 2-1 a district court's determination that Regeneron Pharmaceuticals, Inc.'s patent on genetically modified mice is unenforceable due to inequitable conduct during prosecution of the patent. In Regeneron Pharmaceuticals, Inc. v. Merus N.V., the Federal Circuit upheld the district court's unconventional approach to finding inequitable conduct, holding […]
back to top